Histopathology for Oncology Therapeutics

When developing a cancer therapeutic, understanding how proteins along the targeted metabolic pathway are modulated is essential in understanding the molecule’s mechanism of action. Immunohistochemistry (IHC) is essential in determining protein expression and localization in tissues of interest.

IHC is critical in determining protein biomarker detection, localization, and semi-quantitative expression levels. Through multi-panel IHC testing, one can determine the expression of multiple biomarkers in a biopsied sample with a high level of sensitivity and specificity. Biomarkers play an important role in preclinical studies and identifying potential drug targets.

Our Oncology Expertise

Wax-it Histology Services is a leader in the preclinical evaluation of anti-cancer therapeutics, with a highly specialized team that brings a wealth of expertise in the field of oncology. Wax-it Histology Services is a GLP-recognized facility that focuses its preclinical efforts on:

  • General histology services (paraffin and frozen)
  • Immunohistochemistry services (general IHC, cross-reactivity studies, antibody &      biomarker testing/validation)
  • GLP & non-GLP histopathology for preclinical toxicology studies

Wax-it Histology Services is familiar with a variety of oncology-specific biomarkers including:

(click on any image to launch gallery)

Additional Biomarkers:

  • BRAF
  • BRCA1
  • BRCA2
  • CHK2
  • cFOS
  • c-Kit/ CD117/Stem cell factor receptor
  • Calretinin
  • CA-9 (carbonic anhydrase)
  • EGFR
  • mTOR
  • Nanog
  • p63
  • Topoisomerase 1
  • p21
  • PCNA
  • pTEN
  • s100 4A
  • SFRP1

Request a Scientific Consultation

To discuss your oncology study requiring histopathology, contact Wax-it Histology Services via email at science@waxitinc.com  or by phone at 604.822.1595 to book a complimentary scientific consultation.

More Articles